You are here: Industry Insights > Novartis

News List

New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines worldpharmanews
September 04, 2020
Novartis and the African Union (AU) through the Africa Medical Supplies Platform (AMSP) have announced a new collaboration to facilitate the supply of medicines from the Novartis Pandemic Response Portfolio to the AU member states and Caricom countries.
Novartis' Entresto racks up a heart failure study win—but it's a mixed one fiercepharma
September 01, 2020
As the bestselling drug in the heart failure space, Novartis' Entresto suffered a stinging setback last year in a novel indication—but there were some signs of hope.
Novartis’ ABL001 meets primary endpoint of phase 3 chronic myeloid leukemia study pharmaceutical-business-review
September 01, 2020
Novartis announced that, at primary analysis, the Phase III ASCEMBL study met its primary endpoint of statistically significant superiority in major molecular response (MMR) rate at 24 weeks for asciminib (ABL001) vs. bosutinib.
Novartis analysis shows inclisiran lowers LDL-C with high consistency expresspharma
August 31, 2020
The analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran).
Novartis leans on state-by-state strategy, digital prowess for latest MS launch fiercepharma
August 26, 2020
“None of us have experience launching in a pandemic,” Victor Bultó, Novartis’ U.S. pharma president, acknowledged ahead of last week’s FDA green light for multiple sclerosis med Kesimpta. But the company thinks it’s pretty well set up for the task.
Novartis' CML drug hits PhIII targets pharmatimes
August 26, 2020
Novartis' Phase III ASCEMBL study has met its primary goal showing that asciminib was superior to bosutinib in inducing a major molecular response (MMR) in patients with a certain from of chronic myeloid leukaemia (CML).
Top Pharma & Biopharma Quarterly Results contractpharma
August 26, 2020
Pfizer: 2Q Revenues: $11.8 billion (-11%). 2Q Earnings: $3.4 billion (-32%). YTD Revenues: $23.8 billion (-10%). YTD Earnings: $6.8 billion (-24%)...
Novartis' melanoma combo fails in PhIII pharmatimes
August 24, 2020
Novartis has announced that its investigational immunotherapy spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) failed to improve progression-free survival in patients with advanced melanoma.
European Commission approves Novartis’ Xolair® (omalizumab) europeanpharmaceuticalreview
August 10, 2020
Novartis’ Xolair (omalizumab) has been approved by the European Commission as an add-on therapy with intranasal corticosteroids to treat severe chronic rhinosinusitis with nasal polyps.
EU approves new indication for Novartis’ Xolair pharmatimes
August 07, 2020
The European Commission has approved a new indication for Novartis’ Xolair (omalizumab) as an add-on therapy for the treatment of adults with sever chronic rhinosinusitis with nasal polyps (CRSwNP).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page